Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT04389632

PHASE1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.

Official title: A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1006

Start Date

2020-06-08

Completion Date

2029-03-22

Last Updated

2026-07-06

Healthy Volunteers

Conditions

Carcinoma, Non-Small Cell Lung Squamous Cell Carcinoma of Head and Neck HER2 Negative Breast Neoplasms Esophageal Squamous Cell Carcinoma Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Ovarian Neoplasms Cutaneous Squamous Cell Cancer Exocrine Pancreatic Adenocarcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms Stomach Neoplasms

Interventions

DRUG

sigvotatug vedotin

Administered into the vein (IV; intravenously)

DRUG

pembrolizumab

200mg every 3 weeks or 400mg every 6 weeks, given by IV

DRUG

cisplatin

75 mg/m2 every 3 weeks, given by IV

DRUG

carboplatin

AUC 5 mg/mL per min every 3 weeks, given by IV

Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part). * Non-small cell lung cancer (NSCLC) * Head and neck squamous cell cancer (HNSCC) * Advanced HER2-negative breast cancer * Esophageal squamous cell carcinoma (ESCC) * Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ) * Cutaneous squamous cell cancer (cSCC) * Exocrine pancreatic adenocarcinoma * Bladder cancer * Cervical cancer * Gastric cancer * High grade serous ovarian cancer (HGSOC) * Part A only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic options. * Part B only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies. Participants must have received platinum-based therapy and a PD-1/PD-(L)1 inhibitor, if applicable and available. * Part C only: For pembrolizumab combination cohorts, participants must be eligible for pembrolizumab per local standard of care. For pembrolizumab with cisplatin or carboplatin, participants must be eligible for both pembrolizumab and the platinum agent per local standard of care. Participants must be treatment naïve for locally advanced or metastatic systemic therapy (prior definitively intended or \[neo\]adjuvant therapy is allowed). * Part D only: Participants must be treatment naïve for locally advanced or metastatic systemic therapy. * Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows: * Disease-specific expansion cohorts (Part B and Part D): A baseline fresh tumor biopsy is required. An archival biopsy collected within 90 days prior to first dose of study drug may be used. * Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy * An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Measurable disease per the RECIST v1.1 at baseline Exclusion Criteria * History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. * Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they: * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment, * have no new or enlarging brain metastases, and * are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug. * In Part D, participants with untreated, asymptomatic CNS metastases smaller than 1 cm may be enrolled without definitive treatment as long as they have no neurological symptoms, no or minimal surrounding edema, and no requirements for corticosteroids. * Carcinomatous meningitis * Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6 * Pre-existing neuropathy Grade 1 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) for Parts C and D cohorts with cisplatin or carboplatin; Grade 2 or greater per the NCI CTCAE v5.0 for all other cohorts * Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of sigvotatug vedotin. * Routine antimicrobial prophylaxis is permitted * Grade ≥3 pulmonary disease unrelated to underlying malignancy. This includes clinically severe pulmonary function compromise resulting from clinically significant pulmonary illnesses * Part C and D: Prior therapy with a PD-1 inhibitor, anti-PD-(L)1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune-mediated adverse event (IMAE). * History of noninfectious interstitial lung disease (ILD) or pneumonitis that required steroids, current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening * Known diffusing capacity of the lung for carbon monoxide (DLCO; adjusted for hemoglobin) \<50% predicted * Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Locations (158)

Alaska Oncology and Hematology

Anchorage, Alaska, United States

Highlands Oncology Group

Fayetteville, Arkansas, United States

Highlands Oncology Group

Rogers, Arkansas, United States

Highlands Oncology Group

Springdale, Arkansas, United States

Providence Medical Foundation

Anaheim, California, United States

Providence Medical Foundation

Fullerton, California, United States

Providence St. Jude Medical Center Virginia K Crosson and Infusion Center

Fullerton, California, United States

Cancer and Blood Research Center, LLC

Los Alamitos, California, United States

Cancer and Blood Specialty Clinic

Los Alamitos, California, United States

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

The Regents of the University of California

Los Angeles, California, United States

UCLA Department of Medicine-Hematology/Oncology

Los Angeles, California, United States

UCLA Department of Medicine - Hematology & Oncology

Santa Monica, California, United States

Cancer AND Blood Specialty Clinic

Torrance, California, United States

American Oncology Partners, PA. a Florida professional service corporation, d/b/a Vista Oncology

Fort Myers, Florida, United States

Florida Cancer Specialists & Research Institute, LLC

Fort Myers, Florida, United States

Memorial Cancer Institute

Hollywood, Florida, United States

Memorial Healthcare System

Hollywood, Florida, United States

Florida Cancer Specialists

Orlando, Florida, United States

Memorial Cancer Institute at Memorial Hospital West

Pembroke Pines, Florida, United States

Memorial Hospital West

Pembroke Pines, Florida, United States

Ingalls Family Care Center

Calumet City, Illinois, United States

UChicago Medicine - River East

Chicago, Illinois, United States

The University Of Chicago

Chicago, Illinois, United States

University of Chicago Medical Center

Chicago, Illinois, United States

UChicago Medicine at Ingalls - Flossmoor

Flossmoor, Illinois, United States

UChicago Medicine Ingalls Memorial

Harvey, Illinois, United States

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital

New Lenox, Illinois, United States

The University of Chicago Medicine Center for Advanced Care Orland Park

Orland Park, Illinois, United States

Southern Illinois University - Simmons Cancer Institute

Springfield, Illinois, United States

Springfield Clinic Radiology - 800 Building

Springfield, Illinois, United States

Springfield Clinic Urgent Care Plus

Springfield, Illinois, United States

Springfield Clinic

Springfield, Illinois, United States

Springfield Clinic Main Campus

Springfield, Illinois, United States

Springfield Clinic Radiology - Main Campus

Springfield, Illinois, United States

Springfield Memorial Hospital

Springfield, Illinois, United States

UChicago Medicine at Ingalls - Tinley Park

Tinley Park, Illinois, United States

UChicago Medicine - Northwest Indiana

Crown Point, Indiana, United States

Fort Wayne Medical Oncology and Hematology, Inc

Fort Wayne, Indiana, United States

Community Health Network, Inc

Indianapolis, Indiana, United States

Community Health Network, Inc.

Indianapolis, Indiana, United States

Community Health Network Investigational Drug Services

Indianapolis, Indiana, United States

Community Health Network, Inc.

Indianapolis, Indiana, United States

The University of Kansas Cancer Center, Investigational Drug Services

Fairway, Kansas, United States

The University of Kansas Clinical Research Center

Fairway, Kansas, United States

The University of Kansas Hospital

Kansas City, Kansas, United States

The University of Kansas Medical Center Medical Office Building

Kansas City, Kansas, United States

University of Kansas Hospital Cambridge North Tower A

Kansas City, Kansas, United States

University of Kansas Medical Center Research Institute

Kansas City, Kansas, United States

The University of Kansas Cancer Center - Indian Creek Campus

Overland Park, Kansas, United States

The University of Kansas Cancer Center - Westwood

Westwood, Kansas, United States

University of Kansas Cancer Center

Westwood, Kansas, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham & Women's Hospital

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center,East Campus Research Pharmacy

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Dana-Farber Cancer Institute - Chestnut Hill

Newton, Massachusetts, United States

Allina Health Cancer Institute - Mercy Hospital

Coon Rapids, Minnesota, United States

Allina Health Cancer Institute - Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Allina Health Cancer Institute - United Hospital

Saint Paul, Minnesota, United States

Allina Health Cancer Institute

Saint Paul, Minnesota, United States

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States